Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumour × Fluorouracil × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 199 Rectal Neoplasms 124 Stomach Neoplasms 91 Colonic Neoplasms 80 Pancreatic Neoplasms 72 Esophageal Neoplasms 66 Neoplasm Metastasis 53 Squamous Cell Carcinoma of Head and Neck 40 Head and Neck Neoplasms 38 Adenocarcinoma Of Esophagus 35 Neoplasms 33 Breast Neoplasms 32 Esophageal Squamous Cell Carcinoma 22 Carcinoma, Hepatocellular 21 Cholangiocarcinoma 19 Adenocarcinoma 17 Nasopharyngeal Carcinoma 15 Bile Duct Neoplasms 14 Carcinoma, Squamous Cell 13 Biliary Tract Neoplasms 13 Gallbladder Neoplasms 12 Urinary Bladder Neoplasms 11 Anus Neoplasms 11 Liver Neoplasms 10 Nasopharyngeal Neoplasms 8 Carcinoma 8 Colorectal Cancer Metastatic 7 Recurrence 6 Peritoneal Neoplasms 5 Ovarian Neoplasms 5

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡